CHIC2: A Potential Drug Target Or Biomarker for Leukemia (G26511)

Target Name: CHIC2

NCBI ID: G26511

CHIC2

CHIC2: A Potential Drug Target Or Biomarker for Leukemia

Chloride channels (CHICs) are a family of transmembrane proteins that play a crucial role in various physiological processes, including ion homeostasis and neurotransmission. CHIC2, also known as BrX-like, is a member of the CHIC family that has been identified as a potential drug target or biomarker in the context of leukemia. In this article, we will explore the biology of CHIC2 and its potential as a therapeutic target or biomarker in the treatment of leukemia.

Structure and Function

The CHIC family of proteins consists of four subunits: CHIC1, CHIC2, CHIC3, and CHIC4. All of these subunits contain a catalytic domain, a transmembrane region, and a N-terminus. The catalytic domain is responsible for the synthesis of the unique chloride ions that give the subunits their name. The transmembrane region is responsible for the subcellular localization of the subunits, and the N-terminus is responsible for the interaction with other proteins.

CHIC2 is a 120-kDa protein that is expressed in various tissues, including brain, heart, skeletal muscles, and leukemia cells. It is highly homogeneous and has a Mr of 178,472. CHIC2 is localized to the endoplasmic reticulum (ER) and the trans-endosomal system (TES), which are responsible for the delivery of proteins to various cell types.

CHIC2 functions as a chloride channel that is involved in the regulation of ion homeostasis and neurotransmission. It is a critical protein for the maintenance of the resting membrane potential of nerve and muscle cells and plays a role in the regulation of action potentials.

CHIC2 has been shown to be involved in various signaling pathways, including the regulation of ion homeostasis, neurotransmission, and cell signaling. It has been shown to interact with various proteins, including the neurotransmitter acetylcholine and the protein synaptophysin.

Drug Targeting

CHIC2 has been identified as a potential drug target due to its involvement in various signaling pathways. One of the main targets of CHIC2 is the regulation of ion homeostasis. Ion homeostasis is the maintain of a stable membrane potential that is essential for various cellular processes, including muscle and nerve contractions, and the regulation of ion channels is a critical part of this process.

CHIC2 has been shown to play a role in the regulation of ion homeostasis by allowing the movement of chloride ions into the cell. This process is important for maintaining the resting membrane potential of nerve and muscle cells and is critical for the regulation of action potentials.

Another potential target of CHIC2 is the regulation of neurotransmission. CHIC2 has been shown to interact with the neurotransmitter acetylcholine, which is a critical ligand for the CHIC2 channel. This interaction suggests that CHIC2 may be involved in the regulation of neurotransmission by allowing the movement of chloride ions into the cell.

In addition to its role in ion homeostasis and neurotransmission, CHIC2 has also been shown to be involved in the regulation of cell signaling. It has been shown to interact with the protein synaptophysin, which is a protein that is involved in the regulation of synaptic strength and the maintenance of the postsynaptic potential.

Biomarker Potential

The CHIC2 protein has the potential to serve as a biomarker for various diseases, including leukemia. Leukemia is a cancer that affects the white blood cells,

Protein Name: Cysteine Rich Hydrophobic Domain 2

The "CHIC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHIC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets